Posted by Michael Wonder on 03 Jan 2023
US FDA grants breakthrough designation for blood test to help diagnose inaccessible brain tumours
2 January 2023 - Datar Cancer Genetics now has three breakthrough designations granted by the US FDA, including liquid biopsies for breast and prostate cancer detection.
Datar Cancer Genetics announced today that the US FDA has granted 'breakthrough device designation' for its 'TriNetra-Glio', a blood test to help in the diagnosis of brain tumours.
